Market Research Report
Japanese Encephalitis - Pipeline Review, H2 2017
|Published by||Global Markets Direct||Product code||227543|
|Published||Content info||43 Pages
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H2 2017, provides an overview of the Japanese Encephalitis (Infectious Disease) pipeline landscape.
Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Japanese Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Japanese Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.